Briobacept（研究用级别）

Research Grade Briobacept

货号：RB9T37016004

在您使用本产品前请认真阅读说明书，这对您顺利完成实验很有帮助。

产品编码
RB9T37016004

中文名称
Briobacept（研究用级别）

英文名称
Research Grade Briobacept

形态
Liquid

纯度
>95% purity as determined by SDS-PAGE.

内毒素水平
Please contact the lab for this information.

应用
ELISA, Functional assay, Research in vivo

表达系统
Mammalian Cells

登录号
Q9Y275

抗体亚型
Fusion - [TNFRSF13C (tumor necrosis factor recepto

纯化方式
Protein A/G purified from cell culture supernatant.

浓度
1mg/ml

种属反应性
Human

靶标

BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimula

背景信息

Blisibimod (also known as A-623, formerly AMG 623) is a selective antagonist of B-cell activating factor (BAFF, also known as B-lymphocyte stimulator or BLyS), being developed by Anthera Pharmaceuticals as a treatment for systemic lupus erythematosus. It is currently under active investigation in clinical trials.Mechanism of actionBlisibimod is a fusion protein consisting of four BAFF binding domains fused to the N-terminus of the fragment crystallizable region (Fc) of a human antibody.BAFF is involved in B-cell survival, activation, and differentiation. Elevated levels of BAFF have been associated with several B-cell mediated autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, multiple sclerosis, Sjögren syndrome, Graves' disease, and Hashimoto's thyroiditis. Blisibimod binds to BAFF and inhibits interaction with BAFF receptors, thus decreasing B-cell survival and proliferation throughout the body. Improvements in disease activity have been observed in patients with systemic lupus erythematosus and rheumatoid arthritis following treatment with BAFF inhibitors in clinical trials.DevelopmentBlisibimod was initially developed by Amgen, with Phase I trials demonstrating comparable safety between the blisibimod and placebo treatments. It was subsequently acquired by Anthera Pharmaceuticals, who in 2010 initiated a global Phase II study called PEARL-SC to investigate the efficacy, safety, and tolerability of blisibimod in subjects with systemic lupus erythematosus. The PEARL-SC study, completed in April 2012, yielded data that has been published. Blisibimod is currently being tested in a Phase 3 study, CHABLIS-SC1, for systemic lupus erythematosus, and a Phase 2 study, BRIGHT-SC, for IgA nephropathy.

• Pharmacokinetics and immunological effects of exogenously administered recombinant human B lymphocyte stimulator (BLyS) in mice., PMID:11160623

别名

BR3-Fc, SS-79, 869881-54-9

储存缓冲液

0.01M PBS, pH 7.4.

稳定性和储存

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4° C for short-term storage (1-2 weeks). Store at -20° C for up to 12 months. For long-term storage, store at -80° C.

For research use only. Not suitable for clinical or therapeutic use.